A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination with Endocrine and Targeted Therapies in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Breast Cancer

This is an open-label, multicenter, Phase I study designed to evaluate the safety,
tolerability, and pharmacokinetics of inavolisib administered orally as a single agent in
patients with locally advanced or metastatic PIK3CA-mutant solid tumors, including breast
cancer, and in combination with standard-of-care endocrine and/or targeted therapies for
the treatment of locally advanced or metastatic PIK3CA-mutant breast cancer. Participants
will be enrolled in two stages: a dose-escalation stage (Stage I) and an expansion stage
(Stage II). Participants will be assigned to one of seven regimens: inavolisib as a
single agent (Arm A), inavolisib in combination with palbociclib and letrozole (Arm B),
inavolisib in combination with letrozole (Arm C), inavolisib in combination with
fulvestrant (Arm D), inavolisib in combination with palbociclib and fulvestrant (Arm E),
inavolisib in combination with palbociclib, fulvestrant, and metformin (Arm F), and
inavolisib in combination with trastuzumab and pertuzumab (and letrozole or fulvestrant,
if applicable (Arm G)).

Inclusion Criteria:

- Evaluable or measurable disease per RECIST, Version 1.1 (measurable disease only for
Arm D)

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Life expectancy of greater than or equal to (>=) 12 weeks

- Adequate hematologic and organ function, including blood counts, liver and kidney
function

Stage I Arm A (Inavolisib):

- Locally advanced, recurrent, or metastatic, PIK3CA mutant, incurable solid tumor
malignancy, including breast cancer

Stages I and II, Arms B and C:

- Postmenopausal female participants with locally advanced or metastatic PIK3CA-mutant
HR+/HER2- breast cancer

Stage II, Arms D, E, or F:

- Female participants with locally advanced or metastatic PIK3CA-mutant HR+/HER2-
breast cancer

Stage II Arm D:

- Prior treatment with CDK4/6 inhibitor

Stage II Arm G:

- Female participants with locally advanced or metastatic PIK3CA-mutant HER2+ breast
cancer

- Left ventricular ejection fraction 50% or greater

Stages I and II:

- All participants must provide tumor tissue from the primary or metastatic tumor site
obtained from a prior or new biopsy or surgical procedure for detection of PIK3CA
mutation by central laboratory test.

Exclusion Criteria:

- Metaplastic breast cancer

- History of leptomeningeal disease

- Type 1 or 2 diabetes requiring anti-hyperglycemic medication

- Inability or unwillingness to swallow pills

- Malabsorption syndrome or other condition that would interfere with enteral
absorption

- Known and untreated, or active central nervous system metastases

- Uncontrolled pleural effusion or ascites

- Any active infection that could impact patient safety or serious infection requiring
intravenous antibiotics

- History of other malignancy within 5 years, except for treated carcinoma in situ of
the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer

- History of or active ventricular dysrhythmias or congestive heart failure requiring
medication or symptomatic coronary heart disease

- Congenital long QT syndrome, prolonged QT interval, or family history of sudden
unexplained death or long QT syndrome

Stage II Arms B, C, D, and E only:

- Prior treatment with >1 chemotherapy regimen for metastatic disease

- Prior treatment with PI3K inhibitor

- History of significant toxicity related to mTOR inhibitor requiring treatment
discontinuation

Stage II Arms B and E only:

- Prior CDK4/6 inhibitor treatment

Stage II Arm G only:

- Current uncontrolled hypertension or unstable angina

- History of congestive heart failure, serious cardiac arrhythmia, or recent
myocardial infarction

- Prior ejection fraction decrease on trastuzumab

- Prior cumulative doxorubicin greater than 360 mg/m2

- Symptomatic active lung disease

- History of significant toxicity related to trastuzumab and/or pertuzumab requiring
discontinuation of treatment